I discuss switching from dulaglutide to semaglutide (weekly) or tirzepatide , considering tolerability, coverage, and comorbidities
When to choose KLOW KLOW is the better choice when chronic inflammation is a factor (gut issues, joint inflammation, autoimmune concerns), when you want systemic anti-inflammatory support alongside tissue repair, for healing situations complicated by ongoing inflammation, and for users who have not responded adequately to GLOW alone
Plans that adopt the Caremark template can still exclude weight-loss GLP-1s, and plenty do
Given that obesity is a chronic and relapsing disease, it is important to understand the effectiveness of different strategies to maintain WL: TRIUMPH-6 (NCT06859268) will assess changes in bodyweight at 116 weeks in individuals with obesity who have completed 80 weeks of retatrutide, comparing continued treatment at high or low doses of retatrutide versus switching to placebo for the last 36 weeks
Alles entsprach der Beschreibung und meinen Erwartungen